Johnson & Johnson (NYSE:JNJ) Stock Position Boosted by Foster Victor Wealth Advisors LLC

Foster Victor Wealth Advisors LLC grew its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 3.4% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 84,564 shares of the company's stock after buying an additional 2,798 shares during the period. Foster Victor Wealth Advisors LLC's holdings in Johnson & Johnson were worth $12,831,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also made changes to their positions in the business. Tallon Kerry Patrick purchased a new position in shares of Johnson & Johnson during the fourth quarter worth approximately $290,000. Capital & Planning LLC boosted its holdings in Johnson & Johnson by 13.6% in the 4th quarter. Capital & Planning LLC now owns 1,528 shares of the company's stock valued at $221,000 after purchasing an additional 183 shares in the last quarter. Brighton Jones LLC boosted its position in shares of Johnson & Johnson by 13.9% during the 4th quarter. Brighton Jones LLC now owns 51,876 shares of the company's stock worth $7,502,000 after purchasing an additional 6,332 shares in the last quarter. Union Bancaire Privee UBP SA purchased a new position in Johnson & Johnson in the fourth quarter valued at about $85,886,000. Finally, Viewpoint Capital Management LLC boosted its position in Johnson & Johnson by 5.1% during the fourth quarter. Viewpoint Capital Management LLC now owns 14,051 shares of the company's stock worth $2,032,000 after purchasing an additional 681 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company's stock.

Johnson & Johnson Stock Down 1.2%

Shares of Johnson & Johnson stock traded down $1.86 on Monday, hitting $155.24. 7,022,773 shares of the company's stock traded hands, compared to its average volume of 9,132,877. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43. The firm's 50-day moving average is $153.84 and its 200 day moving average is $153.70. The stock has a market cap of $373.52 billion, a P/E ratio of 23.34, a PEG ratio of 2.56 and a beta of 0.42. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $169.99.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 earnings per share for the quarter, topping the consensus estimate of $2.59 by $0.18. The company had revenue of $21.89 billion during the quarter, compared to analyst estimates of $21.65 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. Equities analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, June 10th. Investors of record on Tuesday, May 27th were paid a dividend of $1.30 per share. This is a positive change from Johnson & Johnson's previous quarterly dividend of $1.24. The ex-dividend date was Tuesday, May 27th. This represents a $5.20 annualized dividend and a yield of 3.35%. Johnson & Johnson's dividend payout ratio is 57.84%.

Wall Street Analysts Forecast Growth

JNJ has been the topic of several recent research reports. Raymond James reduced their price target on shares of Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating on the stock in a report on Monday, April 14th. Wall Street Zen downgraded Johnson & Johnson from a "strong-buy" rating to a "buy" rating in a research report on Thursday, May 22nd. Leerink Partners downgraded Johnson & Johnson from an "outperform" rating to a "market perform" rating and cut their price objective for the stock from $169.00 to $153.00 in a report on Tuesday, May 13th. Bank of America dropped their target price on shares of Johnson & Johnson from $171.00 to $159.00 and set a "neutral" rating for the company in a research report on Thursday, April 10th. Finally, Benchmark raised shares of Johnson & Johnson to a "strong-buy" rating in a research report on Thursday, April 24th. Eleven analysts have rated the stock with a hold rating, eight have given a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat.com, Johnson & Johnson currently has an average rating of "Moderate Buy" and an average price target of $170.88.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.